2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T431,A total of 22 short-term studies comprising 10 962 participants (aripiprazole: n = 1297; brexpiprazole: n = 1973; cariprazine: n = 1894; lumateperone: n = 483; quetiapine extended release [XR]: n = 719; and placebo: n = 4596) were included for analysis. Lumateperone had the highest effect size for efficacy (risk ratio [RR], 1.72; 95% credible interval [CrI], 1.40-2.15), followed by aripiprazole (RR, 1.53; 95% CrI, 1.32-1.77), brexpiprazole (RR, 1.38; 95% CrI, 1.18-1.65), cariprazine (RR, 1.20; 95% CrI, 1.07-1.36), and quetiapine XR (RR, 1.15; 95% CrI, 0.96-1.35). A hierarchy of acceptability was observed, with aripiprazole exhibiting the highest acceptability (RR, 1.16; 95% CrI, 0.89-1.50), followed by cariprazine (RR, 1.44; 95% CrI, 1.15-1.82), brexpiprazole (RR, 1.47; 95% CrI, 1.18-1.85), quetiapine XR (RR, 1.56; 95% CrI, 1.14-2.12), and lumateperone (RR, 2.30; 95% CrI, 1.45-3.84). Secondary outcomes (eg, symptomatic remission) and exploratory outcomes (eg, clinically significant weight gain) accorded with the coprimary outcomes.31:Ta68,Most adults living with major depressive disorder (MDD) fail to achieve remission with conventional antidepressants. The US Food and Drug Administration (FDA) has approved 5 atypical antipsychotics in MDD on the basis of their substantial evidence of efficacy and safety. To compare the efficacy and acceptability of FDA-approved atypical antipsychotics for the adjunctive treatment of MDD in order to provide decision support to practitioners and persons with lived experience. A systematic search was conducted using PubMed/MEDLINE, PsycINFO, the Cochrane Library, and Embase from database inception through July 15, 2025. Six independent raters screened publications for eligibility. Inclusion criteria were atypical antipsychotics that are FDA approved in the adjunctive treatment of MDD. Two independent raters obtained data and examined risk of bias in accordance with the Cochrane criteria. Effect sizes were synthesized using random-effects models. Data were analyzed from August to September 2025. The primary outcomes were efficacy (ie, ≥50% reduction from baseline in the total Montgomery-Åsberg Depression Rating Scale [MADRS] score) and acceptability (ie, all-cause discontinuation). A total of 22 short-term studies comprising 10 962 participants (aripiprazole: n = 1297; brexpiprazole: n = 1973; cariprazine: n = 1894; lumateperone: n = 483; quetiapine extended release [XR]: n = 719; and placebo: n = 4596) were included for analysis. Lumateperone had the highest effect size for efficacy (risk ratio [RR], 1.72; 95% credible interval [CrI], 1.40-2.15), followed by aripiprazole (RR, 1.53; 95% CrI, 1.32-1.77), brexpiprazole (RR, 1.38; 95% CrI, 1.18-1.65), cariprazine (RR, 1.20; 95% CrI, 1.07-1.36), and quetiapine XR (RR, 1.15; 95% CrI, 0.96-1.35). A hierarchy of acceptability was observed, with aripiprazole exhibiting the highest acceptability (RR, 1.16; 95% CrI, 0.89-1.50), followed by cariprazine (RR, 1.44; 95% CrI, 1.15-1.82), brexpiprazole (RR, 1.47; 95% CrI, 1.18-1.85), quetiapine XR (RR, 1.56; 95% CrI, 1.14-2.12), and lumateperone (RR, 2.30; 95% CrI, 1.45-3.84). Secondary outcomes (eg, symptomatic remission) and exploratory outcomes (eg, clinically significant weight gain) accorded with the coprimary outcomes. This systematic review and meta-analysis indicates that differences exist between adjunctive atypical antipsychotics in the treatment of MDD with respect to overall efficacy and acceptability, which should be simultaneously considered. The absence of adequate and well-controlled studies documenting maintenance efficacy of adjunctive atypical antipsychotics in MDD remains a knowledge gap.32:Tfed, Importance Most adults living with major depressive disorder (MDD) fail to achieve remission with conventional antidepressants. The US Food and Drug Administration (FDA) has approved 5 atypical antipsychotics in MDD on the basis of their substantial evidence of efficacy and safety. Objective To compare the efficacy and acceptability of FDA-approved atypical antipsychotics for the adjunctive treatment of MDD in order to provide decision support to practitioners and persons with lived experience. Data Sources A systematic search was conducted using PubMed/MEDLINE, PsycINFO, the Cochrane Library, and Embase from database inception through July 15, 2025. Study Selection Six independent raters screened publications for eligibility. Inclusion criteria were atypical antipsychotics that are FDA approved in the adjunctive treatment of MDD. Data Extraction and Synthesis Two independent raters obtained data and examined risk of bias in accordance with the Cochrane criteria. Effect sizes were synthesized using random-effects models. Data were analyzed from August to September 2025. Main Outcomes and Measures The primary outcomes were efficacy (ie, ≥50% reduction from baseline in the total Montgomery-Åsberg Depression Rating Scale [MADRS] score) and acceptability (ie, all-cause discontinuation). Results A total of 22 short-term studies comprising 10 962 participants (aripiprazole: n = 1297; brexpiprazole: n = 1973; cariprazine: n = 1894; lumateperone: n = 483; quetiapine extended release [XR]: n = 719; and placebo: n = 4596) were included for analysis. Lumateperone had the highest effect size for efficacy (risk ratio [RR], 1.72; 95% credible interval [CrI], 1.40-2.15), followed by aripiprazole (RR, 1.53; 95% CrI, 1.32-1.77), brexpiprazole (RR, 1.38; 95% CrI, 1.18-1.65), cariprazine (RR, 1.20; 95% CrI, 1.07-1.36), and quetiapine XR (RR, 1.15; 95% CrI, 0.96-1.35). A hierarchy of acceptability was observed, with aripiprazole exhibiting the highest acceptability (RR, 1.16; 95% CrI, 0.89-1.50), followed by cariprazine (RR, 1.44; 95% CrI, 1.15-1.82), brexpiprazole (RR, 1.47; 95% CrI, 1.18-1.85), quetiapine XR (RR, 1.56; 95% CrI, 1.14-2.12), and lumateperone (RR, 2.30; 95% CrI, 1.45-3.84). Secondary outcomes (eg, symptomatic remission) and exploratory outcomes (eg, clinically significant weight gain) accorded with the coprimary outcomes. Conclusions and Relevance This systematic review and meta-analysis indicates that differences exist between adjunctive atypical antipsychotics in the treatment of MDD with respect to overall efficacy and acceptability, which should be simultaneously considered. The absence of adequate and well-controlled studies documenting maintenance efficacy of adjunctive atypical antipsychotics in MDD remains a knowledge gap. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Abilify: brand Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Abilify (brand). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/brand/Abilify\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Brands\",\"item\":\"https://www.reachrx.ai/hub/tag/brand\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Abilify\",\"item\":\"https://www.reachrx.ai/hub/tag/brand/Abilify\"}]}}"}}]],["$","$L2f",null,{"title":"Abilify: Research & Clinical Takeaways","description":"See clinical studies on Abilify — efficacy, safety signals, dosing, and head-to-head results.","papers":[{"doi":"10.1001/jamapsychiatry.2026.0658","pmid":"42090141","title":"Adjunctive Antipsychotics in Major Depressive Disorder","journal_title":"JAMA Psychiatry","journal_issn":"2168-622X","published_at":"2026-05-06T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150735/","source_score":88,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamapsychiatry.2026.0658","days":"7","issn":"2168-622X","rank":"8","field":"Clinical Medicine","score":"88","category":"Psychiatry","categories":["Psychiatry"],"_categories":["Psychiatry"]},"pubmed":{"doi":"10.1001/jamapsychiatry.2026.0658","title":"Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.","journal":"JAMA psychiatry","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"42090141","conclusions":"","publication_date":"2026-05-06T00:00:00"},"crossref":{"DOI":"10.1001/jamapsychiatry.2026.0658","URL":"https://doi.org/10.1001/jamapsychiatry.2026.0658","ISSN":["2168-622X"],"link":[{"URL":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/2848529/jamapsychiatry_mcintyre_2026_oi_260019_1777303646.00799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Adjunctive Antipsychotics in Major Depressive Disorder"],"author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neuroscience, University of California, Riverside"}]},{"given":"Sung Ryul","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, Republic of Korea"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy"}]},{"given":"Joseph F.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York"},{"name":"Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York"},{"name":"Charité–Universitätsmedizin Berlin, Berlin, Germany"}]},{"given":"Angela T. H.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, German Center for Mental Health, partner site Berlin, Berlin, Germany"},{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}]},{"given":"Christine E.","family":"Dri","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada"}]},{"given":"Heidi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada"}]},{"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[{"name":"The Early Multimodular Prevention and Intervention Research Institution, Psychiatric Centre North Zealand, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"},{"name":"Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington"}]}],"issued":{"date-parts":[[2026,5,6]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-05-06T15:31:22Z","timestamp":1778081482000,"date-parts":[[2026,5,6]]},"indexed":{"date-time":"2026-05-06T16:16:24Z","timestamp":1778084184274,"date-parts":[[2026,5,6]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2848529"}},"subtitle":["A Systematic Review and Network Meta-Analysis"],"deposited":{"date-time":"2026-05-06T15:31:28Z","timestamp":1778081488000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2168-622X"}],"published":{"date-parts":[[2026,5,6]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1002/wps.21120","key":"yoi260019r1","year":"2023","issue":"3","author":"McIntyre","volume":"22","first-page":"394","unstructured":null,"article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.","journal-title":"World Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)32802-7","key":"yoi260019r2","year":"2018","issue":"10128","author":"Cipriani","volume":"391","first-page":"1357","unstructured":null,"article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1176/ajp.2007.164.2.201","key":"yoi260019r3","year":"2007","issue":"2","author":"Rush","volume":"164","first-page":"201","unstructured":null,"article-title":"STAR*D: what have we learned?","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjopen-2022-063095","key":"yoi260019r4","year":"2023","issue":"7","author":"Pigott","volume":"13","first-page":null,"unstructured":null,"article-title":"What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? a reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol.","journal-title":"BMJ Open","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12888-018-1625-y","key":"yoi260019r5","year":"2018","issue":"1","author":"Mago","volume":"18","first-page":"33","unstructured":null,"article-title":"Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder.","journal-title":"BMC Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2021.4313","key":"yoi260019r6","year":"2022","issue":"4","author":"Henssler","volume":"79","first-page":"300","unstructured":null,"article-title":"Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: a systematic review and meta-analysis.","journal-title":"JAMA Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.v68n0207","key":"yoi260019r7","year":"2007","issue":"2","author":"Thase","volume":"68","first-page":"224","unstructured":null,"article-title":"A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.20230922","key":"yoi260019r8","year":"2024","issue":"1","author":"McIntyre","volume":"181","first-page":"26","unstructured":null,"article-title":"Psychotropic drug-related weight gain and its treatment.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41380-023-02203-y","key":"yoi260019r9","year":"2023","issue":"8","author":"Siafis","volume":"28","first-page":"3267","unstructured":null,"article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.","journal-title":"Mol Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1055/a-1934-9856","key":"yoi260019r10","year":"2023","issue":"1","author":"Nishi","volume":"56","first-page":"5","unstructured":null,"article-title":"Antipsychotic monotherapy for major depressive disorder: a systematic review and meta-analysis.","journal-title":"Pharmacopsychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1097/JCP.0000000000001964","key":"yoi260019r11","year":"2025","issue":"2","author":"Durgam","volume":"45","first-page":"67","unstructured":null,"article-title":"Lumateperone for the treatment of major depressive disorder with mixed features or bipolar depression with mixed features: a randomized placebo-controlled trial.","journal-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1017/S1092852917000165","key":"yoi260019r12","year":"2017","issue":"2","author":"Stahl","volume":"22","first-page":"203","unstructured":null,"article-title":"Guidelines for the recognition and management of mixed depression.","journal-title":"CNS Spectr","doi-asserted-by":"publisher"},{"DOI":"10.1002/wps.20771","key":"yoi260019r13","year":"2020","issue":"3","author":"Maj","volume":"19","first-page":"269","unstructured":null,"article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management.","journal-title":"World Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.25m15848","key":"yoi260019r14","year":"2025","issue":"4","author":"Durgam","volume":"86","first-page":null,"unstructured":null,"article-title":"Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.20250292","key":"yoi260019r15","year":"2025","issue":"12","author":"Durgam","volume":"182","first-page":"1072","unstructured":null,"article-title":"Adjunctive lumateperone in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.2190/T8EM-C8YH-373N-1UWD","key":"yoi260019r17","year":"1997","issue":"2","author":"Leon","volume":"27","first-page":"93","unstructured":null,"article-title":"Assessing psychiatric impairment in primary care with the Sheehan Disability Scale.","journal-title":"Int J Psychiatry Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"yoi260019r18","year":"2007","issue":"7","author":"Busner","volume":"4","first-page":"28","unstructured":null,"article-title":"The Clinical Global Impressions Scale: applying a research tool in clinical practice.","journal-title":"Psychiatry (Edgmont)","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(15)00308-6","key":"yoi260019r19","year":"2015","issue":"10011","author":"Lenze","volume":"386","first-page":"2404","unstructured":null,"article-title":"Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.4178/epih.e2019013","key":"yoi260019r20","year":"2019","issue":null,"author":"Shim","volume":"41","first-page":null,"unstructured":null,"article-title":"Network meta-analysis: application and practice using R software.","journal-title":"Epidemiol Health","doi-asserted-by":"publisher"},{"DOI":"10.4178/epih.e2019008","key":"yoi260019r21","year":"2019","issue":null,"author":"Shim","volume":"41","first-page":null,"unstructured":null,"article-title":"Intervention meta-analysis: application and practice using R software.","journal-title":"Epidemiol Health","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.20220504","key":"yoi260019r22","year":"2023","issue":"3","author":"Sachs","volume":"180","first-page":"241","unstructured":null,"article-title":"Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.22m14643","key":"yoi260019r23","year":"2023","issue":"5","author":"Riesenberg","volume":"84","first-page":null,"unstructured":null,"article-title":"Cariprazine for the adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant therapy: results of a randomized, double-blind, placebo-controlled study.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.64719/pb.4578","key":"yoi260019r24","year":"2018","issue":"4","author":"Earley","volume":"48","first-page":"62","unstructured":null,"article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial.","journal-title":"Psychopharmacol Bull","doi-asserted-by":"publisher"},{"DOI":"10.1097/YIC.0000000000000235","key":"yoi260019r25","year":"2018","issue":"6","author":"Fava","volume":"33","first-page":"312","unstructured":null,"article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.","journal-title":"Int Clin Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.15m10070","key":"yoi260019r26","year":"2016","issue":"3","author":"Durgam","volume":"77","first-page":"371","unstructured":null,"article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1111/pcn.13615","key":"yoi260019r27","year":"2024","issue":"2","author":"Kato","volume":"78","first-page":"113","unstructured":null,"article-title":"Adjunctive brexpiprazole 1?mg and 2?mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.","journal-title":"Psychiatry Clin Neurosci","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.17m12058","key":"yoi260019r28","year":"2018","issue":"4","author":"Hobart","volume":"79","first-page":null,"unstructured":null,"article-title":"A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1080/03007995.2018.1430220","key":"yoi260019r29","year":"2018","issue":"4","author":"Hobart","volume":"34","first-page":"633","unstructured":null,"article-title":"Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.","journal-title":"Curr Med Res Opin","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.14m09689","key":"yoi260019r30","year":"2015","issue":"9","author":"Thase","volume":"76","first-page":"1232","unstructured":null,"article-title":"Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.14m09688","key":"yoi260019r31","year":"2015","issue":"9","author":"Thase","volume":"76","first-page":"1224","unstructured":null,"article-title":"Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1017/neu.2018.23","key":"yoi260019r32","year":"2019","issue":"1","author":"Bauer","volume":"31","first-page":"27","unstructured":null,"article-title":"A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.","journal-title":"Acta Neuropsychiatr","doi-asserted-by":"publisher"},{"DOI":"10.1111/pcn.12663","key":"yoi260019r33","year":"2018","issue":"8","author":"Kamijima","volume":"72","first-page":"591","unstructured":null,"article-title":"Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.","journal-title":"Psychiatry Clin Neurosci","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jad.2013.07.035","key":"yoi260019r34","year":"2013","issue":"3","author":"Kamijima","volume":"151","first-page":"899","unstructured":null,"article-title":"Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).","journal-title":"J Affect Disord","doi-asserted-by":"publisher"},{"DOI":"10.1159/000332050","key":"yoi260019r35","year":"2012","issue":"2","author":"Fava","volume":"81","first-page":"87","unstructured":null,"article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study).","journal-title":"Psychother Psychosom","doi-asserted-by":"publisher"},{"DOI":"10.1017/S1092852900020216","key":"yoi260019r36","year":"2009","issue":"4","author":"Berman","volume":"14","first-page":"197","unstructured":null,"article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.","journal-title":"CNS Spectr","doi-asserted-by":"publisher"},{"DOI":"10.1097/JCP.0b013e31816774f9","key":"yoi260019r37","year":"2008","issue":"2","author":"Marcus","volume":"28","first-page":"156","unstructured":null,"article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.","journal-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1017/S1461145710000015","key":"yoi260019r38","year":"2010","issue":"7","author":"El-Khalili","volume":"13","first-page":"917","unstructured":null,"article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.","journal-title":"Int J Neuropsychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.08m04629","key":"yoi260019r39","year":"2009","issue":"4","author":"Bauer","volume":"70","first-page":"540","unstructured":null,"article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.v68n0604","key":"yoi260019r40","year":"2007","issue":"6","author":"Berman","volume":"68","first-page":"843","unstructured":null,"article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.25m15848","key":"yoi260019r41","year":"2025","issue":"4","author":"Durgam","volume":"86","first-page":null,"unstructured":null,"article-title":"Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.20250292","key":"yoi260019r42","year":"2025","issue":"12","author":"Durgam","volume":"182","first-page":"1072","unstructured":null,"article-title":"Adjunctive lumateperone in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1185/030079908X291958","key":"yoi260019r43","year":"2008","issue":"5","author":"Duru","volume":"24","first-page":"1329","unstructured":null,"article-title":"The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach.","journal-title":"Curr Med Res Opin","doi-asserted-by":"publisher"},{"DOI":"10.1017/S1461145714000224","key":"yoi260019r44","year":"2014","issue":"8","author":"Schalkwijk","volume":"17","first-page":"1343","unstructured":null,"article-title":"Declining efficacy in controlled trials of antidepressants: effects of placebo dropout.","journal-title":"Int J Neuropsychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1111/acps.13260","key":"yoi260019r45","year":"2021","issue":"3","author":"Turkoz","volume":"143","first-page":"253","unstructured":null,"article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.","journal-title":"Acta Psychiatr Scand","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2215-0366(24)00314-6","key":"yoi260019r46","year":"2024","issue":"12","author":"Højlund","volume":"11","first-page":"975","unstructured":null,"article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.","journal-title":"Lancet Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1097/PRA.0000000000000082","key":"yoi260019r47","year":"2015","issue":"4","author":"Preskorn","volume":"21","first-page":"267","unstructured":null,"article-title":"How commonly used inclusion and exclusion criteria in antidepressant registration trials affect study enrollment.","journal-title":"J Psychiatr Pract","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.162.7.1370","key":"yoi260019r48","year":"2005","issue":"7","author":"Zimmerman","volume":"162","first-page":"1370","unstructured":null,"article-title":"Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1017/neu.2024.32","key":"yoi260019r49","year":"2024","issue":null,"author":"McIntyre","volume":"37","first-page":null,"unstructured":null,"article-title":"A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder.","journal-title":"Acta Neuropsychiatr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jad.2016.05.013","key":"yoi260019r50","year":"2016","issue":null,"author":"McIntyre","volume":"201","first-page":"116","unstructured":null,"article-title":"Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials.","journal-title":"J Affect Disord","doi-asserted-by":"publisher"},{"DOI":"10.1097/JCP.0000000000001825","key":"yoi260019r51","year":"2024","issue":"2","author":"McIntyre","volume":"44","first-page":"133","unstructured":null,"article-title":"Effects of adjunctive brexpiprazole on individual depressive symptoms and functioning in patients with major depressive disorder and anxious distress: post hoc analysis of three placebo-controlled studies.","journal-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.3390/ph18070995","key":"yoi260019r52","year":"2025","issue":"7","author":"Barabassy","volume":"18","first-page":"995","unstructured":null,"article-title":"Transdiagnostic efficacy of cariprazine: a systematic review and meta-analysis of efficacy across ten symptom domains.","journal-title":"Pharmaceuticals (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.24m15506","key":"yoi260019r53","year":"2025","issue":"2","author":"Fava","volume":"86","first-page":null,"unstructured":null,"article-title":"Efficacy of adjunctive cariprazine on anxiety symptoms in patients with major depressive disorder: Post hoc analysis of a randomized placebo-controlled trial.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.9758/cpn.23.1106","key":"yoi260019r54","year":"2024","issue":"2","author":"Lee","volume":"22","first-page":"370","unstructured":null,"article-title":"The potential role of aripiprazole augmentation for major depressive disorder with anxious distress in naturalistic treatment setting.","journal-title":"Clin Psychopharmacol Neurosci","doi-asserted-by":"publisher"},{"DOI":"10.1097/JCP.0000000000001420","key":"yoi260019r55","year":"2021","issue":"4","author":"Crapanzano","volume":"41","first-page":"436","unstructured":null,"article-title":"Quetiapine in the anxiety dimension of mood disorders: a systematic review of the literature to support clinical practice.","journal-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jad.2025.05.026","key":"yoi260019r56","year":"2025","issue":"119366","author":"McIntyre","volume":"385","first-page":null,"unstructured":null,"article-title":"The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder.","journal-title":"J Affect Disord","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jpsychires.2023.04.012","key":"yoi260019r57","year":"2023","issue":null,"author":"McIntyre","volume":"162","first-page":"71","unstructured":null,"article-title":"Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: post hoc analysis of Inventory of Depressive Symptomatology Self-Report data.","journal-title":"J Psychiatr Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jad.2017.10.032","key":"yoi260019r58","year":"2018","issue":null,"author":"Scheggi","volume":"227","first-page":"192","unstructured":null,"article-title":"Aripiprazole relieves motivational anhedonia in rats.","journal-title":"J Affect Disord","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2018.18091079","key":"yoi260019r59","year":"2019","issue":"5","author":"Zisook","volume":"176","first-page":"348","unstructured":null,"article-title":"General predictors and moderators of depression remission: a VAST-D report.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1002/da.22063","key":"yoi260019r60","year":"2013","issue":"6","author":"McIntyre","volume":"30","first-page":"515","unstructured":null,"article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.","journal-title":"Depress Anxiety","doi-asserted-by":"publisher"},{"DOI":"10.1111/bdi.70049","key":"yoi260019r61","year":"2025","issue":"5","author":"Xiao","volume":"27","first-page":"347","unstructured":null,"article-title":"The efficacy of pharmacological interventions in the treatment of major depressive disorder and bipolar depression with mixed features: a systematic review.","journal-title":"Bipolar Disord","doi-asserted-by":"publisher"},{"DOI":"10.1017/S1092852925100278","key":"yoi260019r62","year":"2025","issue":"1","author":"Teopiz","volume":"30","first-page":null,"unstructured":null,"article-title":"Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? conceptual and clinical implications.","journal-title":"CNS Spectr","doi-asserted-by":"publisher"},{"DOI":"10.1080/13543784.2025.2522885","key":"yoi260019r63","year":"2025","issue":"6","author":"McIntyre","volume":"34","first-page":"519","unstructured":null,"article-title":"Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder?","journal-title":"Expert Opin Investig Drugs","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.su17009ah1c","key":"yoi260019r64","year":"2017","issue":"8","author":"Jain","volume":"78","first-page":"1091","unstructured":null,"article-title":"Diagnosing and treating patients with mixed features.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2015.15060770","key":"yoi260019r65","year":"2016","issue":"4","author":"Suppes","volume":"173","first-page":"400","unstructured":null,"article-title":"Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-024-03009-2","key":"yoi260019r66","year":"2025","issue":"1","author":"McIntyre","volume":"42","first-page":"246","unstructured":null,"article-title":"Effect of cariprazine on anhedonia in patients with bipolar I depression: post hoc analysis of three randomized placebo-controlled clinical trials.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1097/YIC.0000000000000500","key":"yoi260019r67","year":"2024","issue":"2","author":"Jain","volume":"39","first-page":"82","unstructured":null,"article-title":"Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis.","journal-title":"Int Clin Psychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.4088/JCP.v69n1211","key":"yoi260019r68","year":"2008","issue":"12","author":"Trivedi","volume":"69","first-page":"1928","unstructured":null,"article-title":"Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.","journal-title":"J Clin Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1002/da.21970","key":"yoi260019r69","year":"2012","issue":"7","author":"Thase","volume":"29","first-page":"574","unstructured":null,"article-title":"Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.","journal-title":"Depress Anxiety","doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2020.20081251","key":"yoi260019r70","year":"2021","issue":"5","author":"McIntyre","volume":"178","first-page":"383","unstructured":null,"article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.","journal-title":"Am J Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40263-023-01032-5","key":"yoi260019r71","year":"2023","issue":"10","author":"Akbar","volume":"37","first-page":"867","unstructured":null,"article-title":"Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials.","journal-title":"CNS Drugs","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2204462","key":"yoi260019r72","year":"2023","issue":"21","author":"Lenze","volume":"388","first-page":"2013","unstructured":null,"article-title":"Antidepressant augmentation versus switch in treatment-resistant geriatric depression. reply.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2017.8036","key":"yoi260019r73","year":"2017","issue":"2","author":"Mohamed","volume":"318","first-page":"132","unstructured":null,"article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41380-024-02468-x","key":"yoi260019r74","year":"2024","issue":"8","author":"Papakostas","volume":"29","first-page":"2287","unstructured":null,"article-title":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.","journal-title":"Mol Psychiatry","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0299020","key":"yoi260019r75","year":"2024","issue":"4","author":"Ji","volume":"19","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euroneuro.2024.12.013","key":"yoi260019r76","year":"2025","issue":null,"author":"Vieta","volume":"93","first-page":"29","unstructured":null,"article-title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.","journal-title":"Eur Neuropsychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1017/S1092852924002451","key":"yoi260019r77","year":"2025","issue":"1","author":"McIntyre","volume":"30","first-page":null,"unstructured":null,"article-title":"Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.","journal-title":"CNS Spectr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euroneuro.2024.05.009","key":"yoi260019r78","year":"2024","issue":null,"author":"McIntyre","volume":"85","first-page":"58","unstructured":null,"article-title":"Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.","journal-title":"Eur Neuropsychopharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2304145","key":"yoi260019r79","year":"2023","issue":"14","author":"Reif","volume":"389","first-page":"1298","unstructured":null,"article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jad.2024.04.039","key":"yoi260019r80","year":"2024","issue":null,"author":"Calder","volume":"356","first-page":"753","unstructured":null,"article-title":"Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: a systematic review and meta-analysis.","journal-title":"J Affect Disord","doi-asserted-by":"publisher"},{"DOI":"10.1002/da.20740","key":"yoi260019r81","year":"2010","issue":"10","author":"Liebowitz","volume":"27","first-page":"964","unstructured":null,"article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.","journal-title":"Depress Anxiety","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pnpbp.2021.110480","key":"yoi260019r82","year":"2022","issue":"110480","author":"Fugger","volume":"114","first-page":null,"unstructured":null,"article-title":"Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry","doi-asserted-by":"publisher"},{"DOI":null,"key":"yoi260019r16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Center for Drug Evaluation, US Food & Drug Administration. Major depressive disorder: developing drugs for treatment. April 24, 2020. Accessed July 4, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Psychiatry"],"reference-count":82,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,6]]},"references-count":82,"short-container-title":["JAMA Psychiatry"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamapsychiatry.2026.0658","is_oa":true,"title":"Adjunctive Antipsychotics in Major Depressive Disorder","updated":"2026-05-12T08:54:10+00:00","published_date":"2026-05-06","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150735/","pmh_id":"oai:pubmedcentral.nih.gov:13150735","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13150735/"}}},"created_at":"2026-05-12T13:18:08.265Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"brand","value":"Abilify","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"brand","value":"Caplyta","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"brand","value":"Rexulti","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"brand","value":"Seroquel XR","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"brand","value":"Vraylar","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"condition","value":"Major Depressive Disorder","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"generic","value":"aripiprazole","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"generic","value":"brexpiprazole","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"generic","value":"cariprazine","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"generic","value":"lumateperone","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"generic","value":"quetiapine","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"modality","value":"Atypical Antipsychotic","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"sample_size","value":"n=10962","value_numeric":10962},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"warning","value":"All included trials appear to be industry-sponsored; this was noted as a potential source of bias but was not fully assessable from the available text.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"warning","value":"Lumateperone's superior efficacy ranking should be interpreted cautiously given its notably smaller sample size (n=483 vs. >1,200 for other agents), which can widen credible intervals and inflate point estimates in network meta-analyses.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied because this is the first head-to-head network meta-analysis of all 5 FDA-approved adjunctive agents, but independent replication and long-term data are still lacking.","value_numeric":null},{"paper_doi":"10.1001/jamapsychiatry.2026.0658","tag_type":"warning","value":"The paper is from May 2026 and is very recent; full text was not accessible, so findings are drawn entirely from the abstract and results sections.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and network meta-analysis compared the efficacy (≥50% reduction in MADRS score) and acceptability (all-cause discontinuation) of 5 FDA-approved atypical antipsychotics—aripiprazole, brexpiprazole, cariprazine, lumateperone, and quetiapine XR—as adjunctive treatments in adults with MDD across 22 short-term RCTs (N=10,962).","key_result":"Lumateperone showed the highest efficacy (RR 1.72; 95% CrI 1.40–2.15) but the worst acceptability (RR 2.30; 95% CrI 1.45–3.84 for discontinuation vs. placebo). Aripiprazole had the best acceptability profile (RR 1.16; 95% CrI 0.89–1.50) with strong efficacy (RR 1.53; 95% CrI 1.32–1.77). Quetiapine XR's efficacy did not reach statistical significance (RR 1.15; 95% CrI 0.96–1.35).","limitations":"- Only short-term studies included; no adequate long-term maintenance data exist for any agent.\n- Lumateperone had the smallest sample size (n=483), which may inflate its effect estimate.\n- All trials were industry-sponsored, raising potential risk of bias.","practice_takeaway":"When choosing an adjunctive antipsychotic for MDD, aripiprazole offers the best balance of efficacy and tolerability; lumateperone shows the highest response rate but carries the greatest discontinuation risk. Quetiapine XR's efficacy advantage over placebo was not statistically significant in this analysis."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"brand","value":"Abilify"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Brands","href":"/hub/tag/brand"},{"name":"Abilify"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"brand","hub_tag_value":"Abilify"}}}]]

Papers